Out of curiosity, how do you define "partnership"
Post# of 154138
(Total Views: 473)
Posted On: 11/01/2019 4:47:49 PM
Out of curiosity, how do you define "partnership" differently from an agreement regarding "licensing/commercialization"?
Small spoiler alert here, since I'm running out of posts. Sure, REGN has typically commercialized it's internally-developed (sometimes in partnership with other companies) drugs. But what would preclude them from being an excellent choice (CYDY's perspective) for commercialization for leronlimab, since the development (at least for combo) is essentially done? They have a sales team that is experienced in selling injectable humanized monoclonal antibodies in the United States, and they have successfully commercialized their own compounds. In fact, analysts think that their weakness is in R&D and their pipeline, not their commercialization abilities. Sounds like exactly what CYDY needs, and I doubt REGN would let pride get in the way of having the inside track to distribute a new drug that they don't have to spend the time and money developing. CYDY doesn't necessarily need a "partner" to develop the HIV franchise - although it does need funding for mono - and REGN doesn't need to have a hand in developing leronlimab. It would just be buying a drug to sell it, which tends to work out well for everyone involved according to some guys I knew back in college.
Small spoiler alert here, since I'm running out of posts. Sure, REGN has typically commercialized it's internally-developed (sometimes in partnership with other companies) drugs. But what would preclude them from being an excellent choice (CYDY's perspective) for commercialization for leronlimab, since the development (at least for combo) is essentially done? They have a sales team that is experienced in selling injectable humanized monoclonal antibodies in the United States, and they have successfully commercialized their own compounds. In fact, analysts think that their weakness is in R&D and their pipeline, not their commercialization abilities. Sounds like exactly what CYDY needs, and I doubt REGN would let pride get in the way of having the inside track to distribute a new drug that they don't have to spend the time and money developing. CYDY doesn't necessarily need a "partner" to develop the HIV franchise - although it does need funding for mono - and REGN doesn't need to have a hand in developing leronlimab. It would just be buying a drug to sell it, which tends to work out well for everyone involved according to some guys I knew back in college.
(0)
(0)